|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 113.45 USD | +0.96% |
|
-0.10% | +7.78% |
| 05-13 | European shares lifted by miners and tech; Mideast in focus | RE |
| 05-12 | Merck highlights new long-term data and advancements across broad oncology portfolio and pipeline research at Asco 2026 | RE |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Operating Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Pharmaceutical | 42.75B | 52B | 53.58B | 57.4B | 58.14B | |||||
D&A | 6M | 5M | 5M | 5M | 5M | |||||
Operating Income | 30.98B | 36.85B | 38.88B | 44.53B | 45.75B | |||||
Veterinary Drugs | ||||||||||
Animal Health | 5.57B | 5.55B | 5.62B | 5.88B | 6.35B | |||||
D&A | 158M | 177M | 198M | 256M | 282M | |||||
Operating Income | 1.95B | 1.96B | 1.74B | 1.94B | 2.13B | |||||
Pharmaceutical Contract Manufacturing Services | ||||||||||
Unallocated Other Revenues | 382M | 1.73B | 907M | 891M | 515M | |||||
Operating Income | 156M | 1.16B | 474M | 492M | 251M | |||||
Other | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Operating Income | -1.41B | -1.64B | -1.62B | -1.84B | -2.76B | |||||
Operating Income | -1.64B | -2.08B | -2.04B | -2.4B | -2.79B | |||||
Operating Income | -11.69B | -13.01B | -30.01B | -17.35B | -14.99B |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 22.42B | 27.21B | 28.48B | 32.28B | 36.51B | |||||
Total Assets | 11.76B | 12.89B | 13.92B | 14.72B | 15.02B | |||||
Europe, Middle East and Africa | 13.34B | 14.49B | 13.25B | 14.04B | 14.58B | |||||
Total Assets | 6.08B | 6.99B | 7.56B | 7.55B | 8.86B | |||||
Latin America | 2.21B | 2.58B | 3.09B | 3.46B | 3.41B | |||||
Total Assets | 199M | 225M | 222M | 133M | 128M | |||||
Asia Pacific (other than Japan and China) | 2.41B | 3.61B | 3.22B | 3.06B | 2.98B | |||||
Total Assets | 857M | 966M | 1.02B | 982M | 898M | |||||
Other | 1.22B | 2.57B | 2.1B | 2.56B | 2.88B | |||||
Total Assets | 4M | 5M | 4M | 47M | 51M | |||||
Japan | 2.73B | 3.63B | 3.16B | 3.28B | 2.71B | |||||
Total Assets | 159M | 135M | 133M | 143M | 144M | |||||
China | 4.38B | 5.19B | 6.8B | 5.49B | 1.94B | |||||
Total Assets | 220M | 207M | 193M | 202M | 218M | |||||
Asia Pacific | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - |
- Stock Market
- Equities
- MRK Stock
- Financials Merck & Co., Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition